Robotics, automation to play a ‘fundamental role’ in Icon’s continued success: Q2 earnings call

By Melissa Fassbender

- Last updated on GMT

(Image: Getty/metamorworks)
(Image: Getty/metamorworks)

Related tags Icon CRO Robotics Automation Clinical trial management Clinical trial

Robotics and automation will help improve the clunky and expensive clinical trial process, says Icon CEO – as the company continues to evaluate potential opportunities to improve efficiency.

“Fueled by strong outsourcing trends and a buoyant by a funding environment, market fundamentals remain very positive for the CRO industry,”​ said Steven Cutler, Icon ​CEO, on the company’s recent earnings call.

Cutler said there has been strong market demand across all of the contract research organization’s (CRO) business segments, citing ongoing execution of strategic plans as a contributor to a year-on-year growth of 10%.

Reported revenue for the Q2 2018​ was $641.6m. Full-year 2018 revenue is expected to move from a range of $2.52bn to $2.64bn, to a range of $2.56bn to $2.64bn.

In response to strong business, Cutler said the company needs to ensure it has the staff in place “to cater for the ramp-up in operational activity levels.”

Icon’s headcount grew to 13,650 employees in the second quarter, which is an increase in staff of more than 1,300 employees year-over-year, though approximately half of these employees came in part from the Mapi acquisition in July 2017​.

“We expect to grow and we expect to bring the people on at about the rate of revenue post of what we're going to pursue,”​ Cutler said. Additionally, he noted that the company continues to broaden its customer base and has seen new opportunities for both full service and functional services businesses during the quarter.

Icons also recently expanded its PMG network​ to include the DuPage network of sites​. Cutler said the company is currently looking into other similar networks in North America. Next, it will look to Europe. “We've been actively looking in Europe for a network that we would be able to acquire,”​ he explained.

Progress is expected within the next 12 months, though Cutler hopes it will be earlier.

Robotics and process automation: A medium- to longer-term play

Icon is evaluating the potential opportunities for robotics and process automation through a series of internal projects.

“We believe that there are several areas in the clinical trial process which lend themselves to further efficiencies through the use of robotics process automation, starting with the digitalization of protocol, and the creation of data capture tools as well as testing and validation of applications,”​ said Cutler.

Additionally, within its global business services environment, he believes there is an application for robotics in routine tasks. Cutler cited a demonstration of how the company is improving the designation, categorization, and filing of follow-up letters to monitoring reports.

“A simple thing enough, but a robot can do this in a minute,”​ he said, adding that per its calculations, it takes a person six minutes.

Though the benefits are not just in terms of reduced costs: “being faster and being more up-to-date for audits gives us a quality angle as well as an efficiency angle.”

While a “longer-term play,”​ robotics and automation is part of the company’s strategy and an area of focus, he said.

“I fundamentally believe that the clinical trial process is too clunky and too expensive …We need to be part of the solution there, in making it more efficient, more effective,”​ Cutler added. “I think the robotics is just one aspect of what we can do to improve that and we have a responsibility, and I think an obligation, to do it.”

As for partnerships, Cutler said the company is looking “who’s out there.”

“But we're looking at who are the right partners and what are the right organizations and what are the right technologies,”​ he said, though he notes it is early in the process.

“This is not something that's necessarily going to be implemented within the next quarter or two. As I say, it's a medium- to longer-term play,”​ Cutler explained. “But we do believe it has a fundamental role to play in our continued success.”

The robotics and automation discussion will be expanded – with potential technology demonstrations – at the company’s Analyst Day next month.

Related news

Show more

Related products

show more

The Right CDMO Can Unlock Faster Drug Development

The Right CDMO Can Unlock Faster Drug Development

Content provided by Lonza Small Molecules | 15-May-2023 | Interview

Drug development presents biotech companies with ever-changing challenges. Enabling a faster end-to-end process requires seamless flexibility and extensive...

SDTM supplemental qualifiers explained

SDTM supplemental qualifiers explained

Content provided by Formedix | 12-May-2023 | White Paper

What are SDTM supplemental qualifiers? In short, these are variables in non-CDISC datasets that cannot be mapped to a variable that matches the SDTM standard....

Plan for success with process liquid and buffer preparation

Plan for success with process liquid and buffer preparation

Content provided by Thermo Fisher Scientific - Process Liquid Preparation Services | 25-Apr-2023 | White Paper

Setting the groundwork for successful scale-up is essential for getting a therapeutic to market quickly and efficiently, but navigating the unknowns associated...

Related suppliers

Follow us


View more